The miR‐29 gene family is downregulated in lung cancer, which directly increases the activity of the de novo DNA methyltransferases (DNMTs) DNMT3A and DNMT3B and leads to increased aberrant DNA methylation.[39] More recently, miR‐34b was shown to inhibit DNMTs and histone deacetylases (HDACs) in prostate cancer.[40] Note that miR‐22 also promotes gene expression changes associated with epithelial to mesenchymal transition (EMT) by directly downregulating members of the 10‐11 translocation (TET) family.[41]. The gene discussed is DNMT3A; the disease is prostate carcinoma.